The GV-backed immunotherapy developer has filed for a $57.5m initial public offering that will come after $95m of venture financing.

Arsanis, a US-based immunotherapy developer that counts internet and technology group Alphabet among its investors, has filed to raise up to $57.5m in an initial public offering.

Arsanis is working on monoclonal antibody immunotherapies that will treat serious infectious diseases. Its lead drug candidate, ASN100, is being developed to treat Staphylococcus aureus pneumonia and is in phase 2 clinical trials.

The proceeds will fund clinical development of ASN100 for Staphylococcus aureus pneumonia and other disease indications, and work on…